SPRY - ARS Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.00
DETAILS
HIGH:
$15.00
LOW:
$15.00
MEDIAN:
$15.00
CONSENSUS:
$15.00
UPSIDE:
273.13%
About ARS Pharmaceuticals, Inc. (https://ars-pharma.com)
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian T. Dorsey | Chief Operations Officer | 1969 | $706,970 USD |
| Justin Chakma | Chief Business Officer | 1990 | $682,700 USD |
| Alexander A. Fitzpatrick | Chief Legal Officer & Secretary | 1967 | $677,145 USD |
| Eric Karas | Chief Commercial Officer | 1973 | $618,614 USD |
| Daniel Relovsky | Senior Vice President of Marketing | – | – |
| Donn Casale | CEO, President & Director | 1973 | – |
| Kathleen D. Scott | Chief Financial Officer | – | – |
| Lynda Harris | Vice President of Human Resources | – | – |
| Robert Bell | Co-Founder & Chief Science Officer | – | – |